Yijia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yijia Wang has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Ben Yi
School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China
5 shared publications- Chunze Zhang
School of Medicine, Nankai University, Tianjin, China
5 shared publications Jun Liu
Department of Radiology, The Fourth Central Hospital Affiliated to Nankai University, Tianjin, China
5 shared publicationsTianhao Chu
Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China
5 shared publicationsWei Wang
Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, TEDA Institute of Biological Sciences and Biotechnology, Nankai University
5 shared publicationsZhenying Zhao
Department of Pharmacy, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
5 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1976409
Lipid metabolism mediating oxaliplatin resistance in colorectal cancer
Introduction: As a core drug in chemotherapy regimens for colorectal cancer, the clinical efficacy of oxaliplatin is compromised by multiple resistance mechanisms. Lipid metabolism, a crucial component of metabolic pathways, is known to affect the efficacy of various chemotherapeutic agents. However, to the best of our knowledge, the role of lipid metabolism in oxaliplatin resistance remains unreviewed. Areas covered: In this review, we analyze the relationship between lipid metabolism and oxaliplatin efficacy from the perspectives of DNA damage, ferroptosis, ROS accumulation, cellular dormancy, antitumor immunity, vascular remodeling, and autophagy. This review covers nearly all known oxaliplatin resistance factors, summarizing the regulatory role of lipid metabolism across both basic and clinical studies. Given that clinical studies remain relatively scarce compared to basic research, the impact of factors directly regulated by lipid metabolism on clinical outcomes is analyzed. Based on this, their relationship with oxaliplatin efficacy is inferred, and potential directions for future clinical research are highlighted. Expert opinion/commentary: By summarizing the relationship between lipid metabolism and oxaliplatin resistance, this review provides an important theoretical basis for improving chemotherapy efficacy in colorectal cancer and developing novel combination therapies based on metabolic interventions.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1976409
Open AccessLipid metabolism mediating oxaliplatin resistance in colorectal cancer
Introduction: As a core drug in chemotherapy regimens for colorectal cancer, the clinical efficacy of oxaliplatin is compromised by multiple resistance mechanisms. Lipid metabolism, a crucial component of metabolic pathways, is known to affect the efficacy of various chemotherapeutic agents. However, to the best of our knowledge, the role of lipid metabolism in oxaliplatin resistance remains unreviewed. Areas covered: In this review, we analyze the relationship between lipid metabolism and oxaliplatin efficacy from the perspectives of DNA damage, ferroptosis, ROS accumulation, cellular dormancy, antitumor immunity, vascular remodeling, and autophagy. This review covers nearly all known oxaliplatin resistance factors, summarizing the regulatory role of lipid metabolism across both basic and clinical studies. Given that clinical studies remain relatively scarce compared to basic research, the impact of factors directly regulated by lipid metabolism on clinical outcomes is analyzed. Based on this, their relationship with oxaliplatin efficacy is inferred, and potential directions for future clinical research are highlighted. Expert opinion/commentary: By summarizing the relationship between lipid metabolism and oxaliplatin resistance, this review provides an important theoretical basis for improving chemotherapy efficacy in colorectal cancer and developing novel combination therapies based on metabolic interventions.
- Open Access
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1944826
Ellagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1
Introduction: Drug resistance in colorectal cancer frequently leads to chemotherapy failure. The application of small-molecule compounds to enhance chemotherapy efficacy has become a common therapeutic strategy. Ellagic acid, a natural polyphenol in plants, is abundantly contained in herbal medicines used for adjuvant chemotherapy against colorectal cancer. Nevertheless, the regulatory effect of ellagic acid on oxaliplatin-based chemotherapy remains unclear. Methods: Cell Counting Kit-8 and colony formation assays were used to evaluate the efffcacy of the combination of ellagic acid and oxaliplatin. Network pharmacology, Human Phospho-Kinase Array, co-immunoprecipitation and thermal shift assay were used to screen potential targets of ellagic acid in chemotherapy sensitization. Transfection of overexpression plasmids and shRNAs against these targets was performed to verify the underlying mechanism. Tumor tissues derived from colorectal cancer patients were used to establish PDX models for in vivo experiments. All cells and tissues used in this study have wild-type TP53 . Results: Cellular experiments demonstrated that ellagic acid exerts a synergistic effect with oxaliplatin. Target screening revealed that ellagic acid inhibits Wip1, thereby upregulating p53 and resulting in the synergistic anti-tumor effect. Further studies demonstrated that ellagic acid interacts to ATM and suppresses ATM phosphorylation, thereby downregulating Wip1 via the ATM/ AMPK/HIPK2 signaling pathway. Data from FOLFOX chemotherapy indicated that high Wip1 expression correlates with poor prognosis. PDX models demonstrated that ellagic acid enhances the therapeutic efficacy of oxaliplatin, particularly in tumors with high Wip1 expression. Discussion: Our findings indicate that ellagic acid enhances the antitumor efficacy of oxaliplatin in colorectal cancer with wild-type TP53 and high Wip1 expression.
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1944826
Open AccessEllagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1
Introduction: Drug resistance in colorectal cancer frequently leads to chemotherapy failure. The application of small-molecule compounds to enhance chemotherapy efficacy has become a common therapeutic strategy. Ellagic acid, a natural polyphenol in plants, is abundantly contained in herbal medicines used for adjuvant chemotherapy against colorectal cancer. Nevertheless, the regulatory effect of ellagic acid on oxaliplatin-based chemotherapy remains unclear. Methods: Cell Counting Kit-8 and colony formation assays were used to evaluate the efffcacy of the combination of ellagic acid and oxaliplatin. Network pharmacology, Human Phospho-Kinase Array, co-immunoprecipitation and thermal shift assay were used to screen potential targets of ellagic acid in chemotherapy sensitization. Transfection of overexpression plasmids and shRNAs against these targets was performed to verify the underlying mechanism. Tumor tissues derived from colorectal cancer patients were used to establish PDX models for in vivo experiments. All cells and tissues used in this study have wild-type TP53 . Results: Cellular experiments demonstrated that ellagic acid exerts a synergistic effect with oxaliplatin. Target screening revealed that ellagic acid inhibits Wip1, thereby upregulating p53 and resulting in the synergistic anti-tumor effect. Further studies demonstrated that ellagic acid interacts to ATM and suppresses ATM phosphorylation, thereby downregulating Wip1 via the ATM/ AMPK/HIPK2 signaling pathway. Data from FOLFOX chemotherapy indicated that high Wip1 expression correlates with poor prognosis. PDX models demonstrated that ellagic acid enhances the therapeutic efficacy of oxaliplatin, particularly in tumors with high Wip1 expression. Discussion: Our findings indicate that ellagic acid enhances the antitumor efficacy of oxaliplatin in colorectal cancer with wild-type TP53 and high Wip1 expression.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling
Background: Cetuximab is an approved therapy for metastatic colorectal cancer (CRC) with wild-type RAS and BRAF; however, additional resistance mechanisms beyond genetic mutations remain poorly understood. Butyrate, a key metabolite produced by the gut microbiome and present in the circulatory system, has been reported to supply cellular energy and modulate the epidermal growth factor receptor (EGFR) downstream signaling pathway. However, whether butyrate affects the resistance to cetuximab is still unknown. Methods: In this work, Cell Counting Kit-8 (CCK-8) and colony formation assays were used to evaluate the efficacy of cetuximab. Glycolysis/oxidative phosphorylation (OXPHOS) Assay Kit was applied to assess metabolic activity. Human Phospho-Kinase Array and RNA sequencing were employed to screen targets of butyrate. Overexpression plasmids and short hairpin RNAs (shRNAs) targeting these molecules were transfected into cells for further validation. Subcutaneous tumor and pulmonary metastasis models were used for in vivo studies. Results: The findings showed that physiological concentrations of butyrate increased cetuximab resistance in KRAS wild-type cells only. Further investigation found that butyrate upregulated EGFR signaling through facilitating the binding reaction between epidermal growth factor (EGF) and EGFR. In parallel, butyrate activated AMP-activated protein kinase (AMPK)–wild-type p53-induced phosphatase 1 (Wip1) signaling, leading to suppression of p53 and p38 mitogen-activated protein kinase (p38 MAPK)-mediated pro-apoptotic signaling. These two mechanisms are the reason that butyrate attenuates the efficacy of cetuximab. Results of subcutaneous tumor and pulmonary metastasis models exhibited a similar conclusion to in vitro experiments. Conclusion: Butyrate reduces cetuximab efficacy in KRAS wild-type colorectal cancer through EGFR and AMPK–Wip1 signaling, and may represent a candidate predictive biomarker for treatment response.
- 1 January 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Open AccessCirculating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling
Background: Cetuximab is an approved therapy for metastatic colorectal cancer (CRC) with wild-type RAS and BRAF; however, additional resistance mechanisms beyond genetic mutations remain poorly understood. Butyrate, a key metabolite produced by the gut microbiome and present in the circulatory system, has been reported to supply cellular energy and modulate the epidermal growth factor receptor (EGFR) downstream signaling pathway. However, whether butyrate affects the resistance to cetuximab is still unknown. Methods: In this work, Cell Counting Kit-8 (CCK-8) and colony formation assays were used to evaluate the efficacy of cetuximab. Glycolysis/oxidative phosphorylation (OXPHOS) Assay Kit was applied to assess metabolic activity. Human Phospho-Kinase Array and RNA sequencing were employed to screen targets of butyrate. Overexpression plasmids and short hairpin RNAs (shRNAs) targeting these molecules were transfected into cells for further validation. Subcutaneous tumor and pulmonary metastasis models were used for in vivo studies. Results: The findings showed that physiological concentrations of butyrate increased cetuximab resistance in KRAS wild-type cells only. Further investigation found that butyrate upregulated EGFR signaling through facilitating the binding reaction between epidermal growth factor (EGF) and EGFR. In parallel, butyrate activated AMP-activated protein kinase (AMPK)–wild-type p53-induced phosphatase 1 (Wip1) signaling, leading to suppression of p53 and p38 mitogen-activated protein kinase (p38 MAPK)-mediated pro-apoptotic signaling. These two mechanisms are the reason that butyrate attenuates the efficacy of cetuximab. Results of subcutaneous tumor and pulmonary metastasis models exhibited a similar conclusion to in vitro experiments. Conclusion: Butyrate reduces cetuximab efficacy in KRAS wild-type colorectal cancer through EGFR and AMPK–Wip1 signaling, and may represent a candidate predictive biomarker for treatment response.
- Open Access
- 1 January 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (1) , 59-73
Cancer Cell Dormancy and Chemotherapy Resistance
Cancer cell dormancy is associated with tumor recurrence and metastasis. Chemotherapy usually induces dormancy as external pressure on the tumor. Dormant cells have considerable resistance to antitumor drugs, although they are not harmful to the host if they do not wake up. Chemotherapy induces a dormant phenotype through remodeling of the tumor microenvironment and alteration of intracellular signaling networks. Multiple adaptive mechanisms that confer drug resistance have been identified in these dormant cells, including the unfolded protein response to endoplasmic reticulum stress, metabolic reprogramming favoring oxidative phosphorylation to avoid damage from oxidative stress, and autophagy to realize the circular utilization of energy. However, dormancy is reversible. The conversion between dormancy and awakening of the tumor during chemotherapy and the recovery period after treatment is modulated by several factors, including the dose and cycle of treatment, and individual differences among patients. The direct elimination of cancer cells or permanent dormancy by chemotherapy predicts favorable outcomes. According to this theory, understanding the mechanisms of cancer dormancy and awakening under chemotherapy and improving prognosis using suitable treatment strategies requires further investigation. This review analyzed studies on cancer cell dormancy and response to chemotherapy to identify potential novel interests for future studies and probable strategies to optimize chemotherapy in clinical trials.
- 1 January 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (1) , 59-73
Open AccessCancer Cell Dormancy and Chemotherapy Resistance
Cancer cell dormancy is associated with tumor recurrence and metastasis. Chemotherapy usually induces dormancy as external pressure on the tumor. Dormant cells have considerable resistance to antitumor drugs, although they are not harmful to the host if they do not wake up. Chemotherapy induces a dormant phenotype through remodeling of the tumor microenvironment and alteration of intracellular signaling networks. Multiple adaptive mechanisms that confer drug resistance have been identified in these dormant cells, including the unfolded protein response to endoplasmic reticulum stress, metabolic reprogramming favoring oxidative phosphorylation to avoid damage from oxidative stress, and autophagy to realize the circular utilization of energy. However, dormancy is reversible. The conversion between dormancy and awakening of the tumor during chemotherapy and the recovery period after treatment is modulated by several factors, including the dose and cycle of treatment, and individual differences among patients. The direct elimination of cancer cells or permanent dormancy by chemotherapy predicts favorable outcomes. According to this theory, understanding the mechanisms of cancer dormancy and awakening under chemotherapy and improving prognosis using suitable treatment strategies requires further investigation. This review analyzed studies on cancer cell dormancy and response to chemotherapy to identify potential novel interests for future studies and probable strategies to optimize chemotherapy in clinical trials.
- 29 August 2025
- Published by Elsevier in Food Microbiology
- Vol. 134, 104922
An improved real-time quantitative PCR assay for the differentiation of major Listeria monocytogenes serovars
- 29 August 2025
- Published by Elsevier in Food Microbiology
- Vol. 134, 104922
An improved real-time quantitative PCR assay for the differentiation of major Listeria monocytogenes serovars
- 10 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 17
Phillygenin regulates the colorectal cancer tumor microenvironment by inhibiting hypoxia-inducible factor 1 alpha
Background The tumor microenvironment (TME) is important in the recurrence and metastasis of colorectal cancer (CRC). Phillygenin is an effective component of Forsythiae fructus that has long been used in cancer therapy. The mechanism by which phillygenin regulates the TME remains unknown. Methods and Results: A co-culture system of CRC cells and Jurkat T cells was used to simulate the TME in vitro. Network pharmacology and Human XL cytokine arrays were used to preliminarily evaluate the role of phillygenin in the TME. The target of phillygenin was determined using transfection of plasmid-producing overexpression of hypoxia-inducible factor 1 alpha (HIF-1α) overexpression or abrogated HIF-1α expression via short hairpin RNA plasmid. The therapeutic effect of phillygenin in vivo was assessed in a subcutaneous tumor mouse model. In vitro, phillygenin enhanced the immune response of T cells and prevented the immune escape of cancer cells via the inhibition of HIF-1α. Phillygenin upregulated interleukin (IL)-2 and downregulates IL-10 and FOXP3 in Jurkat T cells co-cultured with CRC cells. Phillygenin inhibited expressions of HIF-1α, transforming growth factor-beta, vascular endothelial growth factor, and CD31 in CRC cells cultured alone or with Jurkat T cells. Phillygenin considerably suppressed tumor growth and improved the TME in vivo. Conclusions: Phillygenin can enhance the immune response and inhibit angiogenesis in the TME in CRC by inhibiting HIF-1α.
- 10 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 17
Phillygenin regulates the colorectal cancer tumor microenvironment by inhibiting hypoxia-inducible factor 1 alpha
Background The tumor microenvironment (TME) is important in the recurrence and metastasis of colorectal cancer (CRC). Phillygenin is an effective component of Forsythiae fructus that has long been used in cancer therapy. The mechanism by which phillygenin regulates the TME remains unknown. Methods and Results: A co-culture system of CRC cells and Jurkat T cells was used to simulate the TME in vitro. Network pharmacology and Human XL cytokine arrays were used to preliminarily evaluate the role of phillygenin in the TME. The target of phillygenin was determined using transfection of plasmid-producing overexpression of hypoxia-inducible factor 1 alpha (HIF-1α) overexpression or abrogated HIF-1α expression via short hairpin RNA plasmid. The therapeutic effect of phillygenin in vivo was assessed in a subcutaneous tumor mouse model. In vitro, phillygenin enhanced the immune response of T cells and prevented the immune escape of cancer cells via the inhibition of HIF-1α. Phillygenin upregulated interleukin (IL)-2 and downregulates IL-10 and FOXP3 in Jurkat T cells co-cultured with CRC cells. Phillygenin inhibited expressions of HIF-1α, transforming growth factor-beta, vascular endothelial growth factor, and CD31 in CRC cells cultured alone or with Jurkat T cells. Phillygenin considerably suppressed tumor growth and improved the TME in vivo. Conclusions: Phillygenin can enhance the immune response and inhibit angiogenesis in the TME in CRC by inhibiting HIF-1α.
- 22 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155647
Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy
- 22 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155647
Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy
- 16 February 2024
- Published by Elsevier in Phytomedicine
- Vol. 126, 155462
Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways
- 16 February 2024
- Published by Elsevier in Phytomedicine
- Vol. 126, 155462
Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways
- Open Access
- 15 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1238694
Marsdenia tenacissima enhances immune response of tumor infiltrating T lymphocytes to colorectal cancer
Introduction: Tumor-infiltrating T lymphocytes in the tumor microenvironment are critical factors influencing the prognosis and chemotherapy outcomes. As a Chinese herbal medicine, Marsdenia tenacissima extract (MTE) has been widely used to treat cancer in China. Its immunoregulatory effects on tumor-associated macrophages is well known, but whether it regulates tumor-infiltrating T-cell functions remains unclear.Method: We collected 17 tumor samples from MTE-administered colorectal cancer patients, 13 of which showed upregulation of CD3+/CD8+ tumor-infiltrating T cells. Further in vitro and in vivo experiments were performed to investigate the regulatory effects of MTE on tumor-infiltrating T cells and immune escape of tumors.Results: Under single and co-culture conditions, MTE inhibited TGF-β1 and PD-L1 expression in the colorectal cancer (CRC) cell lines HCT116 and LoVo. In Jurkat cells, MTE inhibited FOXP3 and IL-10 expression, increased IL-2 expression, but had no effect on PD-1 expression. These findings were confirmed in vitro using subcutaneous and colitis-associated CRC mouse models. MTE also increased the density of CD3+/CD8+ tumor-infiltrating T cells and exhibited considerable tumor-suppressive effects in these two tumor mouse models.Conclusions: Our findings suggested that MTE inhibits the immune escape of cancer cells, a precipitating factor increasing the immune response of T lymphocytes.
- 15 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1238694
Open AccessMarsdenia tenacissima enhances immune response of tumor infiltrating T lymphocytes to colorectal cancer
Introduction: Tumor-infiltrating T lymphocytes in the tumor microenvironment are critical factors influencing the prognosis and chemotherapy outcomes. As a Chinese herbal medicine, Marsdenia tenacissima extract (MTE) has been widely used to treat cancer in China. Its immunoregulatory effects on tumor-associated macrophages is well known, but whether it regulates tumor-infiltrating T-cell functions remains unclear.Method: We collected 17 tumor samples from MTE-administered colorectal cancer patients, 13 of which showed upregulation of CD3+/CD8+ tumor-infiltrating T cells. Further in vitro and in vivo experiments were performed to investigate the regulatory effects of MTE on tumor-infiltrating T cells and immune escape of tumors.Results: Under single and co-culture conditions, MTE inhibited TGF-β1 and PD-L1 expression in the colorectal cancer (CRC) cell lines HCT116 and LoVo. In Jurkat cells, MTE inhibited FOXP3 and IL-10 expression, increased IL-2 expression, but had no effect on PD-1 expression. These findings were confirmed in vitro using subcutaneous and colitis-associated CRC mouse models. MTE also increased the density of CD3+/CD8+ tumor-infiltrating T cells and exhibited considerable tumor-suppressive effects in these two tumor mouse models.Conclusions: Our findings suggested that MTE inhibits the immune escape of cancer cells, a precipitating factor increasing the immune response of T lymphocytes.
- 16 June 2023
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 40 (4) , 339-356
Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells
Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is extensively used for clinical therapy in KRAS wild-type colorectal cancer (CRC) patients. However, some patients still cannot get benefit from the therapy, because metastasis and resistance occur frequently after cetuximab treatment. New adjunctive therapy is urgently needed to suppress metastasis of cetuximab-treated CRC cells. In this study, we used two KRAS wild-type CRC cells, HT29 and CaCo2, to investigate whether platycodin D, a triterpenoid saponin isolated from Chinese medicinal herb Platycodon grandifloras, is able to suppress the metastasis of cetuximab-treated CRC. Label-free quantitative proteomics analyses showed that platycodin D but not cetuximab significantly inhibited expression of β-catenin in both CRC cells, and suggested that platycodin D counteracted the inhibition effect of cetuximab on cell adherence and functioned in repressing cell migration and invasion. Western blot results showed that single platycodin D treatment or combined platycodin D and cetuximab enhanced inhibition effects on expressions of key genes in Wnt/β-catenin signaling pathway, including β-catenin, c-Myc, Cyclin D1 and MMP-7, compared to single cetuximab treatment. Scratch wound-healing and transwell assays showed that platycodin D combined with cetuximab suppressed migration and invasion of CRC cells, respectively. Pulmonary metastasis model of HT29 and CaCo2 in nu/nu nude mice consistently showed that combined treatment using platycodin D and cetuximab inhibited metastasis significantly in vivo. Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D.
- 16 June 2023
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 40 (4) , 339-356
Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells
Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is extensively used for clinical therapy in KRAS wild-type colorectal cancer (CRC) patients. However, some patients still cannot get benefit from the therapy, because metastasis and resistance occur frequently after cetuximab treatment. New adjunctive therapy is urgently needed to suppress metastasis of cetuximab-treated CRC cells. In this study, we used two KRAS wild-type CRC cells, HT29 and CaCo2, to investigate whether platycodin D, a triterpenoid saponin isolated from Chinese medicinal herb Platycodon grandifloras, is able to suppress the metastasis of cetuximab-treated CRC. Label-free quantitative proteomics analyses showed that platycodin D but not cetuximab significantly inhibited expression of β-catenin in both CRC cells, and suggested that platycodin D counteracted the inhibition effect of cetuximab on cell adherence and functioned in repressing cell migration and invasion. Western blot results showed that single platycodin D treatment or combined platycodin D and cetuximab enhanced inhibition effects on expressions of key genes in Wnt/β-catenin signaling pathway, including β-catenin, c-Myc, Cyclin D1 and MMP-7, compared to single cetuximab treatment. Scratch wound-healing and transwell assays showed that platycodin D combined with cetuximab suppressed migration and invasion of CRC cells, respectively. Pulmonary metastasis model of HT29 and CaCo2 in nu/nu nude mice consistently showed that combined treatment using platycodin D and cetuximab inhibited metastasis significantly in vivo. Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D.